Secondary forms of metabolic dysfunction-associated steatotic liver disease (MASLD) have different pathogeneses, ...

NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis ... Conversely, some drugs that improve NASH ...

The latest data from the open-label part of the phase 3 trial showed that 300 mg Aramchol reduced hepatic fibrosis assessed using both conventional and digital pathology as well ... variety of ...

This meta-analysis concluded that MASLD (diagnosed by liver imaging, International Classification of Diseases codes or liver histology) conferred a pooled ... factors in MASLD would also attenuate ...

HealthDay News — Waist-to-height ratio (WHtR) outperforms body mass index (BMI) in detecting the risk for liver disease, according to a study published in the July issue of the Journal of the ...

Waist-to-height ratio had a better predictive value than BMI in assessing liver fibrosis and steatosis outcomes across ages and racial groups.

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, ...

Hepatic steatosis is defined by an increased content of hepatocellular lipids (HCLs) and is frequently observed in insulin-resistant states including type 2 diabetes mellitus. A dietary excess of ...

There was no association observed between lower income and increased fibrosis among New York City residents with metabolic dysfunction-associated steatohepatitis (MASH).

had smaller liver biopsies, more metabolic risk factors, more extensive fibrosis and more grades 2 4 steatosis than the three other groups. Validation group 2 with HCV cured patients had quasi ...

MAFLD was diagnosed on the basis of liver steatosis detected by ultrasonography and/or persistently elevated alanine aminotransferase concentrations (> 52 U/L for boys and > 44 U/L for girls).